If this trial is representative of R327's usefulness, an expansion to other test sites ought to lead to comparable results that would indicate excellent efficacy for R327. In a market that sees a cost to even the US healthcare system alone of US$9-13B per year, can you imagine what a new drug that 'cures' DFI like these within a couple of weeks of topical treatment is going to be worth to the company in revenues?
Ann: Positive Ph I/II DFI Efficacy Data to Support Site Expansion, page-7
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
49.0¢ |
Change
0.010(2.08%) |
Mkt cap ! $112.3M | |||
| Open | High | Low | Value | Volume |
| 47.0¢ | 49.5¢ | 47.0¢ | $40.52K | 83.40K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 271056 | 48.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 49.5¢ | 73889 | 2 |
View Market Depth
| Last trade - 11.57am 08/08/2024 (20 minute delay) ? |
| RCE (ASX) Chart |